Research programme: transforming growth factor beta receptor kinase inhibitors - Bristol-Myers Squibb/Rigel

Drug Profile

Research programme: transforming growth factor beta receptor kinase inhibitors - Bristol-Myers Squibb/Rigel

Alternative Names: TGF beta receptor kinase inhibitors - Bristol-Myers Squibb/Rigel

Latest Information Update: 18 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Bristol-Myers Squibb; Rigel Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Feb 2015 Bristol-Myers Squibb collaborates with Rigel Pharmaceuticals to develop TGF-β protein kinase inhibitors for Cancer
  • 23 Feb 2015 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top